Metabolic syndrome and urinary cGMP excretion in general population

To examine the relationship between metabolic syndrome and enclothelial dysfunction, we investigated cross-sectionally the correlation between metabolic risk factors and urinary excretion of cyclic guanosine 3',5'-monophosphate (cGMP), a second messenger of nitric oxide (NO), in 1541 Japanese men and women aged 40-79 years. The 24-h urinary excretion of cGMP was measured using a I-125-labeled cGMP radioimmunoassay and was adjusted for urinary creatinine excretion (nmol/mmol creatinine). The components of metabolic fasting plasma glucose >= 6.11 mmol/l or syndrome were defined based on the following criteria: body mass index (BMI) >= 25.0 kg/m(2), non-fasting plasma glucose level > 11.1 mmol/l, systolic blood pressure >= 130 mm Hg or diastolic blood pressure > 85 mm Hg, high-density lipoprotem (HDL)-cholesterol < 1.03 mmol/l for men and < 1.29 mmol/l for women, and triglyceride >= 1.69 minol/l. The number of components of metabolic syndrome correlated inversely with urinary cGNIP excretion; means of cGMP excretion for the whole group adjusted for age, sex, and cardiovascular risk factors were 53.6, 48.6, 47.9, 44.4 and 42.3 muol/mmol for 0, 1, 2, 3. and 4-5 components of metabolic syndrome, respectively (p=0.002). Our data suggest that a reduction of NO bioactivity concur with clustered features of the metabolic syndrome. (c) 2006 Elsevier Ireland Ltd. All rights reserved.